A nuclear waste cleanup specialist that treats, processes, and disposes of radioactive and hazardous materials for government and commercial clients, like a hazmat hospital for the nation's most dangerous leftovers.
Revenue is tiny at USD 0.06B annually, with gross margins swinging from 18% in 2023 to negative in 2025—the company loses money on every dollar, posting net losses of USD 0.01B to USD 0.02B, so no profitable business currently pays the bills.
Licensed nuclear treatment facilities and decades of regulatory expertise create high barriers, but competitors like Veolia and Clean Harbors can bid on the same government contracts, and the company's negative margins show pricing power is weak.
Key events, in time order
Q2 call confirms expansion plan, consistent with existing Hanford subcontract event line, incremental confirmation
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
